Mohamed, M., Elamawy, M., Marei, Y., Mohamed, M., Eleleimy, H. (2023). Effect of Lymphoma Treatment on Development of New Onset Diabetes. test, 10(11), 11-15. doi: 10.21608/ejhbmt.2023.415978
Maha AA. Mohamed; Medhat M. Elamawy; Yasmin M. Marei; Mohamed A. Mohamed; Hiam AM. Eleleimy. "Effect of Lymphoma Treatment on Development of New Onset Diabetes". test, 10, 11, 2023, 11-15. doi: 10.21608/ejhbmt.2023.415978
Mohamed, M., Elamawy, M., Marei, Y., Mohamed, M., Eleleimy, H. (2023). 'Effect of Lymphoma Treatment on Development of New Onset Diabetes', test, 10(11), pp. 11-15. doi: 10.21608/ejhbmt.2023.415978
Mohamed, M., Elamawy, M., Marei, Y., Mohamed, M., Eleleimy, H. Effect of Lymphoma Treatment on Development of New Onset Diabetes. test, 2023; 10(11): 11-15. doi: 10.21608/ejhbmt.2023.415978

Effect of Lymphoma Treatment on Development of New Onset Diabetes

Egyptian Journal of Hematology and Bone Marrow Transplantation
Volume 10, Issue 11, April 2023, Pages 11-15    PDF (267.6 K)
Document Type: Original Article
DOI: 10.21608/ejhbmt.2023.415978
Authors
Maha AA. Mohamed* 1; Medhat M. Elamawy2; Yasmin M. Marei3; Mohamed A. Mohamed2; Hiam AM. Eleleimy2
1Internal Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt
2Internal Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.
3Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Benha University, Benha, Egypt.
Abstract
Background: Lymphoma, a heterogeneous malignancy of lymphocytes, is commonly treated with chemotherapy regimens like R-CHOP, which include glucocorticoids known to induce hyperglycemia and potentially cause new-onset diabetes or worsen existing diabetes. This study aimed to evaluate the effect of lymphoma treatment on the development of new-onset diabetes and related complications.


Methods: This observational cohort study included 61 lymphoma patients: 39 non-diabetic and 22 diabetic. Detailed history, physical exams, and lab investigations (FBS, 2-hour postprandial blood sugar, and HbA1c) were conducted before and after treatment.


Results: In the non-diabetic group, 23.1% developed new-onset diabetes. These patients had higher mean weight (85 ± 8 kg vs. 79 ± 7 kg, P = 0.046) and BMI (28.5 ± 3.2 vs. 23.4 ± 1.7, P < 0.001). Post-treatment, fasting blood sugar increased (123 ± 20 mg/dL vs. 90 ± 10 mg/dL, P < 0.001), as did 2-hour postprandial blood sugar (179 ± 31 mg/dL vs. 138 ± 16 mg/dL, P = 0.003) and HbA1c (5.9 ± 0.4% vs. 5.1 ± 0.3%, P < 0.001). BMI increase significantly predicted new-onset diabetes (OR = 1.984, 95% CI = 1.205–3.267, P = 0.007). In the diabetic group, 72.7% experienced complications, with higher post-treatment HbA1c levels (8.4 ± 0.7% vs. 7.5 ± 1%, P = 0.033) and more complications in those treated with R-CHOP (87.5% vs. 33.3%, P = 0.025).


Conclusions: Lymphoma treatments, especially those with steroids like R-CHOP, significantly increase the risk of new-onset diabetes and related complications, necessitating careful glucose monitoring and management.
Keywords
Lymphoma; Chemotherapy; R-CHOP; New-onset diabetes
Statistics
Article View: 49
PDF Download: 17